TRV027   Click here for help

GtoPdb Ligand ID: 6902

Synonyms: TRV 120027 | TRV-027 | TRV-120027 | TRV120027
Compound class: Peptide
Comment: TRV027 (TRV120027) is a synthetic analogue of endogenous angiotensin II peptide [5]. It acts as a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). TRV027 inhibits angiotensin II-mediated vasoconstriction, increases cardiomyocyte contractility and induces an anti-apoptotic effect, all of which when combined, provide a cardioprotective result.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CNCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)O)C)Cc1[nH]cnc1)[C@H](CC)C)Cc1ccc(cc1)O)C(C)C)CCCN=C(N)N
Isomeric SMILES CNCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)O)C)Cc1[nH]cnc1)[C@H](CC)C)Cc1ccc(cc1)O)C(C)C)CCCN=C(N)N
InChI InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1
InChI Key XIEWFECSPPTVQN-KMIMAYJXSA-N
References
1. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett Jr JC. (2011)
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.
Circ Heart Fail, 4 (6): 770-8. [PMID:21835984]
2. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett Jr JC. (2012)
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Circ Heart Fail, 5 (5): 627-34. [PMID:22891045]
3. Pang PS, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P et al.. (2017)
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
Eur Heart J, 38 (30): 2364-2373. [PMID:28459958]
4. Soergel DG, Subach RA, Cowan CL, Violin JD, Lark MW. (2013)
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.
J Clin Pharmacol, 53 (9): 892-9. [PMID:23813302]
5. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. (2010)
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.
J Pharmacol Exp Ther, 335 (3): 572-9. [PMID:20801892]